Adia Med, Inc 8-K, filed Oct 13, 2026
Adia Med, Inc. (ADIA)
About this 8-K
Adia Med, Inc filed this 8-K on October 13, 2026, reporting on events of October 9, 2026.
Adia Med, Inc. fully repaid and discharged its unsecured revolving line of credit facility on October 9, 2026, paying Larry Powalisz a total of $934,970.94 and satisfying all outstanding principal and accrued interest. AI summary
Items reported
- Item 1.02: Ended a material agreement
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Commission File Number:
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(g) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02. Termination of a Material Definitive Agreement
On October 9, 2026, Adia Med, Inc. (the “Company”) fully repaid and discharged its unsecured revolving line of credit facility originally entered into on June 30, 2024, between Larry Powalisz, Chief Executive Officer of the Company, as lender (the “Lender”), and the Company (and its relevant subsidiaries, as applicable), as borrower.
The Facility had been increased over time to a commitment of $1,000,000 by the Lender, to best accommodate the growth needs of the Company, and bore interest at 6% per annum calculated daily.
In satisfaction of the obligation to the Lender, the Company made the following payments to the Lender:
| · | October 7, 2026: $500,000; | |
| · | October 9, 2026: $434,970.94 (of which $74,658.94 constituted accrued interest, and the balance applied to principal). |
Total amount paid to the Lender was $934,970.94.
The Lender has acknowledged that the outstanding principal balance and all accrued interest under the Facility have been paid in full as of October 9, 2026. As a result, the Facility is satisfied in full, with respect to all amounts owing through that date.
The Lender, a related party, is the Chief Executive Officer of the Company.
The foregoing facility is satisfied and discharged and qualified in its entirety by reference to the full text of the Paid-in-Full Acknowledgment dated October 9, 2026, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description of Exhibit |
| 10.1 | Paid-in-Full Acknowledgment of Unsecured Revolving Line of Credit, dated October 9, 2026, by Larry Powalisz as Lender and acknowledged by Adia Med, Inc. |
| 104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101). |
| 2 |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 13, 2026
|
ADIA MED, INC.
/s/ Larry Powalisz Name: Larry Powalisz Title: Chief Executive Officer
/s/ Rebecca Miller Name: Rebecca Miller Title: Chief Financial Officer |
| 3 |
Exhibit 10.1
PAID-IN-FULL ACKNOWLEDGMENT
Unsecured Revolving Line of Credit
Date: October 9, 2026
Lender: Larry Powalisz, Chief Executive Officer
Borrower: Adia Med, Inc. (and its relevant subsidiaries, as applicable)
Original Facility Date: June 30, 2024
Acknowledgment
Reference is made to the unsecured revolving line of credit facility originally dated June 30, 2024, as increased most recently to a commitment of $1,000,000, bearing interest at 6% per annum calculated daily, between Larry Powalisz, as lender, and Adia Med, Inc., as borrower.
The Lender acknowledges receipt and application of the following payments from the Borrower:
| · | October 7, 2026: $500,000 | |
| · | October 9, 2026: $434,970.94, of which $74,658.94 constitutes accrued interest and the remainder is applied to principal |
Total amount received: $934,970.94, including $74,658.94 in accrued interest.
The Lender hereby acknowledges that the outstanding principal balance and all accrued interest under the line of credit have been paid in full as of October 9, 2026. The facility is satisfied and discharged with respect to all amounts owing through that date. This acknowledgment is effective upon receipt of the October 9, 2026 payment in cleared funds.
Lender Acknowledgment
| By: | /s/ Larry Powalisz | |
| Larry Powalisz | ||
| Chief Executive Officer | ||
| Lender | ||
| Date: 10-09-26 | ||
The undersigned, on behalf of Adia Med, Inc., acknowledges the foregoing payment and satisfaction of the amounts owing under the facility through October 9, 2026.
| ADIA MED, INC. | ||
| By: | /s/ Rebecca Miller | |
| Rebecca Miller | ||
| Chief Financial Officer | ||
| Date: 10/09/2026 | ||